US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Liquidia Corporation - Common Stock (NQ:LQDA)

28.64 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Liquidia (NASDAQ:LQDA) High Growth Momentum Meets a Pre-Breakout Setup ↗
Via Chartmill
Liquidia (NASDAQ:LQDA): Strong Growth Paired With Technical Setup Quality ↗
Via Chartmill
LIQUIDIA CORP (NASDAQ:LQDA) Fits the Affordable Growth Screen ↗
Via Chartmill
News headline image
Liquidia (LQDA) Q2 2026 Earnings Call Transcript ↗
YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy. 
Via The Motley Fool
Topics Earnings
Liquidia Corp (NASDAQ:LQDA) Shows High Growth Momentum With a Breakout Setup ↗
Via Chartmill
LIQUIDIA CORP (NASDAQ:LQDA): A High Growth Stock with a Strong Technical Setup ↗
Via Chartmill
News headline image
Why Liquidia Stock Was Diving This Week ↗
It needed to post a blowout quarter instead of the good one it delivered. 
Via The Motley Fool
News headline image
Liquidia Q2 Earnings Call Highlights ↗
Liquidia (NASDAQ:LQDA) reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical... 
Via MarketBeat
Topics Earnings
Liquidia Corp (NASDAQ:LQDA): An Affordable Growth Stock With Explosive Revenue Momentum and Reasonable Forward Valuation ↗
Via Chartmill
News headline image
Transcript: Liquidia Q1 2026 Earnings Conference Call ↗
Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call... 
Via Benzinga
Topics Earnings
Liquidia Corp. (NASDAQ:LQDA) Flashes Perfect 10/10 Technical Score on Minervini Trend Template and High Growth Momentum ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA): Affordable Growth Play With Explosive Revenue ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA) Smashes Q1 Estimates as YUTREPIA Adoption Accelerates ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA): High Growth Momentum Setup Nears Breakout ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA) Presents a High-Growth Momentum and Technical Setup ↗
Via Chartmill
News headline image
What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260% ↗
Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market. 
Via The Motley Fool
News headline image
Liquidia (LQDA) Q1 2026 Earnings Transcript ↗
Liquidia (LQDA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Liquidia Q1 Earnings Call Highlights ↗
Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and... 
Via MarketBeat
Topics Earnings
Liquidia Corp (NASDAQ:LQDA) Shows High-Growth Momentum and Minervini Trend Alignment ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA) Reports Q4 2025 Profitability and Revenue Beat Driven by YUTREPIA Launch ↗
Via Chartmill
News headline image
This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth ↗
This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S. market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million ↗
Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its core market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock? ↗
This biotech focused on pulmonary therapies reported a notable insider sale amid strong share price gains and rising revenue. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M ↗
Biotech innovator Liquidia, focused on therapies for rare conditions, reported a notable insider sale amid strong recent share performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia Stock Up 135% as Insider Sells $1.3 Million in Shares ↗
This biotech innovator in rare disease therapies reported significant insider selling amid a year of robust stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart ↗
Dave Inc. delivers digital banking and personal finance tools designed to offer alternatives to traditional banking platforms. 
Via The Motley Fool
Topics ETFs
News headline image
Liquidia (LQDA) Q4 2025 Earnings Call Transcript ↗
Liquidia (LQDA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗
Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone. 
Via Stocktwits
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >